Tivozanib (Renal Cell Carcinoma) - Analysis and Forecasts to 2022



Summary



GlobalData’s pharmaceuticals report, “Tivozanib (Renal Cell Carcinoma) - Analysis and Forecasts to 2022” provides Tivozanib sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2016-2022). The report also includes information on Renal Cell Carcinoma market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.



Scope


- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Tivozanib including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Tivozanib including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2016-2022 for Tivozanib in the seven major markets



Reasons to buy


- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2016-2022 for all seven major markets

Table Of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 RCC 5
2.1.1 Types of Renal Cell Carcinoma 5
2.2 RCC Market 6
2.3 Epidemiology 6
2.4 Pathophysiology 9
2.5 Etiology 9
2.5.1 Cigarette Smoking 9
2.5.2 Obesity 10
2.5.3 Acquired Cystic Disease 10
2.5.4 Hypertension 10
2.5.5 Family History of Kidney Cancer 10
2.5.6 High Blood Pressure 10
2.5.7 Usage of Certain Medicines 10
2.5.8 Advanced Kidney Disease 10
2.5.9 Gender and Race 10
2.5.10 Genetic and Hereditary Risk Factors 11
2.5.11 Symptoms 11
2.5.12 Diagnosis 12
2.6 GlobalData Report Guidance 14
3 RCC Disease: Market Characterization 15
3.1 RCC Disease Market 15
3.2 RCC Disease Market Forecasts and CAGR 15
3.3 Drivers for the RCC Disease Market 15
3.3.1 High Incidence 16
3.3.2 High Prevalence 17
3.3.3 Emergence of Targeted Therapies 17
3.3.4 Large Unmet Need 17
3.4 Tumor-Node-Metastases (TNM) Classification of RCC 18
3.4.1 Staging 18
3.4.2 Grading 21
3.4.3 Prognosis 21
3.5 Treatment Options in RCC 22
3.5.1 Surgery 22
3.5.2 Radiation therapy 23
3.5.3 Chemotherapy 23
3.5.4 Targeted Therapies 23
3.5.5 Tyrosine Kinase Inhibitors 25
3.5.6 Mammalian Target of Rapamycin (mTOR) Inhibitor 25
3.5.7 Vascular Endothelial Growth Factor (VEGF) Inhibitor 26
3.5.8 Treatment by Stage 26
3.6 Classification of Patients with RCC 29
4 Tivozanib (AV-951) 30
4.1 Introduction 30
4.2 Mechanism of Action 30
4.3 Clinical Studies 30
4.4 Factors Affecting Sales of Tivozanib 31
4.4.1 Superior most Progression Free Survival 31
4.4.2 Acceptable Safety Profile 31
4.4.3 Combinational Therapy 31
4.4.4 Sequential Therapy 31
4.5 Drug Evaluation 32
4.5.1 Drug Risk Benefit Score 32
4.5.2 Intensity of Competition 33
4.6 Sales Forecasts 33
4.6.1 Target Patient Pool of Tivozanib 33
4.6.2 Dosing 34
4.6.3 Market Penetration 34
4.6.4 Annual Cost of Therapy 35
4.6.5 Sales Projections of Tivozanib 35
5 Appendix 44
5.1 Market Definitions 44
5.2 Abbreviations 44
5.3 Research Methodology 44
5.3.1 Coverage 44
5.3.2 Secondary Research 45
5.3.3 Forecasting 45
5.3.4 Number of Patients Approved to Take the Drug 45
5.3.5 Net Penetration of Drug 46
5.3.6 Net Annual Dosing 46
5.3.7 Annual Cost of Therapy 46
5.4 Drug Sales Estimates Model 46
5.5 Contact Us 46
5.6 Disclaimer 46
6 Sources 47

List of Tables

Table 1: RCC, Incidences and Mortality, 2008-2030 8
Table 2: RCC, TNM Classification 18
Table 3: RCC, Fuhrman grading system 21
Table 4: RCC, Treatment Guidelines 22
Table 5: Efficacy of Tivozanib v/s Nexavar in Phase III clinical trial 31
Table 6: Tivozanib, Renal Cell Carcinoma, Drug Risk Benefit Score (1st line therapy) 32
Table 7: Tivozanib, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2013-2022 35
Table 8: Tivozanib, Renal Cell Carcinoma, The US, Sales Estimates ($m), 2013-2022 36
Table 9: Tivozanib, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2013-2022 37
Table 10: Tivozanib, Renal Cell Carcinoma, France, Sales Estimates ($m), 2013-2022 38
Table 11: Tivozanib, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2013-2022 39
Table 12: Tivozanib, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2013-2022 40
Table 13: Tivozanib, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2013-2022 41
Table 14: Tivozanib, Renal Cell Carcinoma, Japan, Sales Estimates ($m), 2013-2022 42

List of Figures

Figure 1: Worldwide Incidence and Mortality Distribution of Top 20 Cancers (%), 2010 7
Figure 2: Total number of cigarettes consumed, The US, 1976-2006 9
Figure 3: RCC, Global, Market Size Forecasts ($bn), 2010-2022 15
Figure 4: RCC, Global, Incidence (in million), 2008-2030 16
Figure 5: Oncology, Worldwide, Incidence (in million), 2008-2030 16
Figure 6: RCC, TNM Staging System 19
Figure 7: RCC, Marketed drug targets 24
Figure 8: RCC, Surgical Management 27
Figure 9: Treatment Algorithm for Metastatic Renal Cell Carcinoma 28
Figure 10: Classification of Patients with RCC 29
Figure 11: Drug Model Diagram of Tivozanib 34
Figure 12: Tivozanib, Renal Cell Carcinoma, Global, Sales Estimates ($m), 2013-2022 35
Figure 13: Tivozanib, Renal Cell Carcinoma, The US, Sales Estimates ($m), 2013-2022 36
Figure 14: Tivozanib, Renal Cell Carcinoma, The UK, Sales Estimates ($m), 2013-2022 37
Figure 15: Tivozanib, Renal Cell Carcinoma, France, Sales Estimates ($m), 2013-2022 38
Figure 16: Tivozanib, Renal Cell Carcinoma, Germany, Sales Estimates ($m), 2013-2022 39
Figure 17: Tivozanib, Renal Cell Carcinoma, Italy, Sales Estimates ($m), 2013-2022 40
Figure 18: Tivozanib, Renal Cell Carcinoma, Spain, Sales Estimates ($m), 2013-2022 41
Figure 19: Tivozanib, Renal Cell Carcinoma, Japan, Sales Estimates ($m), 2016-2022 42
Figure 20: Tivozanib, Renal Cell Carcinoma, Global, Sales Distribution by Country (%), 2022 43
Figure 21: Patients Approved for the Drug 45

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

Drug and Medication Industry: Prostate Cancer – Pipeline Review, H1 2012

  • $ 2 500
  • Company report
  • June 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Prostate Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

Pathology in United States: Fatty Liver Disease – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology Industry: Depression – Pipeline Review, H1 2012

Pathology Industry: Depression – Pipeline Review, H1 2012

  • $ 2 000
  • Company report
  • April 2014
  • by Global Markets Direct

This report provides data on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.